Search - tctmd.com

Displaying 281 - 300 of 612

Sort: Relevancy | Date

News Industry News

Drug-Coated Balloon Shown To Be Superior To Conventional Angioplasty In Treating Superficial Femoral Artery Disease After Two Years

October 14, 2015

News Conference News TCT 2015

TUXEDO-India Affirms Superiority of EES in Patients With Diabetes

Todd Neale

October 14, 2015

News Conference News TCT 2015

IN.PACT SFA: Benefits of DCB Persist at 2 Years

October 14, 2015

Presentation TCT 2015

TCT 50: Peri-strut Low-Intensity Area Assessed by Midterm Follow-up Optical Coherence Tomography May Predict Target Lesion Revascularization After Stent Implantation

Presenter: Stephan Achenbach, Marc D. Feldman, Koji Kuroda

October 13, 2015

News Conference News TCT 2015

Thrombus Aspiration Fails to Reduce Microvascular Obstruction in Subacute STEMI

October 13, 2015

News Conference News TCT 2015

SORT-OUT VI: 3-Year Outcomes Similar With BES, ZES

October 13, 2015

News Conference News TCT 2015

CENTURY II: Bioresorbable-Polymer DES Safe, Effective at 2 Years

October 13, 2015

News Conference News TCT 2015

Second-Generation DES, DCB Both Strategies for Treating In-Stent Restenosis

October 12, 2015

News Conference News TCT 2015

Intracoronary Brachytherapy Reduces DES ISR but Restenosis not Eliminated

October 12, 2015

News Industry News

First-In-Man Study Examines Angiographic And Clinical Outcomes Of Newest Bioresorbable Magnesium Stent

October 12, 2015

News Industry News

Clinical Trial Demonstrates That A Bioresorbable Scaffold is Non-Inferior To A Drug-Eluting Stent In Chinese Patients With Coronary Artery Disease

October 12, 2015

News Conference News TCT 2015

BIOSOLVE-II: Novel Absorbable Scaffold Safe, Effective

October 12, 2015

News Conference News TCT 2015

ABSORB III: Novel Bioresorbable Scaffold as Good as Standard-of-Care DES

Yael L. Maxwell

October 12, 2015

News Industry News

ABSORB III: Clinical Trial Demonstrates That A Bioresorbable Scaffold Is Non-Inferior To A Drug-Eluting Stent In Patients With Coronary Artery Disease

October 12, 2015

News Industry News

ABSORB II: Two-Year Data From The First Randomized Comparison Between Bioresorbable Vascular Scaffolds and Everolimus-Eluting Metallic Stents Show Comparable Patient Outcomes

October 12, 2015

News Conference News TCT 2015

ABSORB II: Absorb BVS, Xience Yield Similar Outcomes at 2 Years

October 12, 2015

News Daily News

Observational Study Sheds Light on Endovascular vs Surgical Options for Symptomatic PAD

L.A. McKeown

October 05, 2015

News Industry News

Boston Scientific Receives FDA Approval For SYNERGY™ Bioabsorbable Polymer Drug-Eluting Stent System

October 05, 2015

News Daily News

High Restenosis Rate After CTO Bailout Technique Linked to Suboptimal Flow

September 15, 2015

News Industry News

First Patient Enrolled in CeloNova’s e-COBRA Clinical Registry

September 14, 2015

Advertisement

Drug-Coated Balloon Shown To Be Superior To Conventional Angioplasty In Treating Superficial Femoral Artery Disease After Two Years

TUXEDO-India Affirms Superiority of EES in Patients With Diabetes

IN.PACT SFA: Benefits of DCB Persist at 2 Years

TCT 50: Peri-strut Low-Intensity Area Assessed by Midterm Follow-up Optical Coherence Tomography May Predict Target Lesion Revascularization After Stent Implantation

Thrombus Aspiration Fails to Reduce Microvascular Obstruction in Subacute STEMI

SORT-OUT VI: 3-Year Outcomes Similar With BES, ZES

CENTURY II: Bioresorbable-Polymer DES Safe, Effective at 2 Years

Second-Generation DES, DCB Both Strategies for Treating In-Stent Restenosis

Intracoronary Brachytherapy Reduces DES ISR but Restenosis not Eliminated

First-In-Man Study Examines Angiographic And Clinical Outcomes Of Newest Bioresorbable Magnesium Stent

Clinical Trial Demonstrates That A Bioresorbable Scaffold is Non-Inferior To A Drug-Eluting Stent In Chinese Patients With Coronary Artery Disease

BIOSOLVE-II: Novel Absorbable Scaffold Safe, Effective

ABSORB III: Novel Bioresorbable Scaffold as Good as Standard-of-Care DES

ABSORB III: Clinical Trial Demonstrates That A Bioresorbable Scaffold Is Non-Inferior To A Drug-Eluting Stent In Patients With Coronary Artery Disease

ABSORB II: Two-Year Data From The First Randomized Comparison Between Bioresorbable Vascular Scaffolds and Everolimus-Eluting Metallic Stents Show Comparable Patient Outcomes

ABSORB II: Absorb BVS, Xience Yield Similar Outcomes at 2 Years

Observational Study Sheds Light on Endovascular vs Surgical Options for Symptomatic PAD

Boston Scientific Receives FDA Approval For SYNERGY™ Bioabsorbable Polymer Drug-Eluting Stent System

High Restenosis Rate After CTO Bailout Technique Linked to Suboptimal Flow

First Patient Enrolled in CeloNova’s e-COBRA Clinical Registry

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content